Welcome to our dedicated page for Biocorrx SEC filings (Ticker: BICX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
a company that changes lives biocorrx® is a leading edge healthcare solutions company focused on improving the lives of those struggling with alcohol and opioid addiction. designed to treat alcoholism and certain opioid addictions, the biocorrx® recovery program is used by a network of independently owned and operated treatment centers located throughout the united states. the program consists of a proprietary long-lasting implant of the fda approved medication, naltrexone, which is proven to substantially reduce cravings for drugs and alcohol. it's a high-quality, comprehensive and cost- effective recovery program built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering addicts.BioCorRx Inc. entered into a stock exchange agreement with three insider shareholders, issuing 2,263,371 shares of its common stock in exchange for 1,215 shares of BioCorRx Pharmaceuticals, Inc., its majority‑owned subsidiary, representing about 12.15% of the subsidiary’s outstanding common stock.
The exchange aligns with a Plan of Reorganization adopted on February 25, 2026, under which BioCorRx intends to acquire control of the subsidiary within the meaning of Sections 368(a)(1)(B) and 368(c) of the Internal Revenue Code. The transaction closed on March 27, 2026 and was approved by the board under the company’s related party transaction policy.
The new BioCorRx shares were issued as unregistered, “restricted securities” in a private transaction relying on Section 4(a)(2) of the Securities Act, involved no cash consideration, and provide the participating shareholders with specified registration rights for their newly issued shares.
BioCorRx Inc. reports another year of losses in 2025 while advancing its addiction-treatment pipeline and adding a commercial product. The company posted a loss from operations of $3,508,763 and a net loss to common shareholders of $3,440,146, and its auditors expressed substantial doubt about its ability to continue as a going concern.
The business centers on the Beat Addiction Recovery program, the UnCraveRx weight-loss program, and lead drug candidate BICX104, a long-acting naltrexone implant for opioid and alcohol use disorders and methamphetamine use disorder. Grant income rose to $2,435,848 in 2025, supported by a multi‑year NIDA award totaling $11,029,977 to fund BICX104 research.
In March 2025, a subsidiary acquired rights to Lucemyra, an FDA‑approved opioid‑withdrawal medication, with a $400,000 upfront purchase price paid from a share of future Lucemyra sales plus 500,000 shares and 500,000 warrants. The company also raised equity at $0.35 per share, issuing over 5 million new shares alongside warrants, contributing to dilution. As of March 27, 2026, it had 26,402,874 common shares outstanding and continues to depend on grants and external financing to fund operations.
BioCorRx (BICX) filed its Q3 2025 10‑Q, highlighting its first meaningful product revenue following the Lucemyra asset purchase. Supply and distribution sales reached $635,224 for the quarter and $946,572 year‑to‑date, driving total net sales of $948,362 for the nine months. The company recorded a Q3 net loss attributable to BioCorRx of $1,917,873 and a year‑to‑date loss of $3,992,701, reflecting higher operating expenses as the business scales.
Cash was $287,688 with a working capital deficit of $13,575,951, and management disclosed substantial doubt about the company’s ability to continue as a going concern. Total assets rose to $7,533,473, including intangible assets of $3,011,833 and goodwill of $2,840,400 tied to the US WorldMeds Lucemyra acquisition, while total liabilities were $20,297,768. The company recognized Q3 grant income of $867,130 under NIDA awards and reported a grant receivable of $761,515 and deferred grant revenue of $56,590. Operating expenses increased to $2,580,811 in Q3, including research and development of $1,004,660 and SG&A of $1,145,353, leading to a Q3 operating loss of $1,945,587.